

Kayexalate

Cat. No.:	HY-148162
CAS No.:	37349-16-9
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

Kayexalate

BIOLOGICAL ACTIVITY

Description	Kayexalate, a cation-exchange resin, is an orally active plasma potassium inhibitor. Kayexalate can be used in the research of hyperkalemia ^{[1][2]} .	
In Vivo	Propiomazine (5 g/kg, oral gavage) lowers serum Li concentrations in CD-1 mice ^[2] . Propiomazine (5 g/kg, oral gavage) reduces serum K concentrations in CD-1 mice ^[3] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	CD-1 mice given with LiCl (125 mg/kg, i.v.) ^[2]
	Dosage:	5 g/kg
	Administration:	Oral gavage, at 20, 40, 90, 150, and 210 minutes after LiCl challenge.
	Result:	Effectively enhanced the elimination of intravenously administered Li.

REFERENCES

- [1]. Harel Z, et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. *Am J Med.* 2013 Mar;126(3):264.e9-24.
- [2]. J G Linakis, et al. Enhancement of lithium elimination by multiple-dose sodium polystyrene sulfonate. *Acad Emerg Med.* 1997 Mar;4(3):175-8.
- [3]. Linakis JG, et al. Sodium polystyrene sulfonate treatment for lithium toxicity: effects on serum potassium concentrations. *Acad Emerg Med.* 1996 Apr;3(4):333-7.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA